MSB News and Press, Mesabi Trust From 06/17/25

2025-06-17 03:15:19 ET Foreword Read the full article on Seeking Alpha For further details see: Buy 6 Ideal Safe Dividend Power Dogs For June

Vesuvius Plc ADR (CKSNY) is expected to report for Q1 2025 Derwent London Plc (DWVYF) is expected to report for Q1 2025 Mapath Capital Corp (IVFZF) is expected to report for quarter end 2025-03-31 Mesabi Trust (MSB) is expected to report for Q1 2026 Seneca Foods Corp. Class B Comm...

Mesabi Trust (MSB) is expected to report for Q1 2026

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway ...

2025-06-03 11:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2025-05-16 09:40:51 ET Summary Dividend Power strategy focuses on high earnings yield and top dividend yield stocks, aiming for strong returns and resilience in downturns. Top projected picks for May include ZIM Integrated Shipping, Mesabi Trust, and Golden Ocean, offering high yi...

NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received seven years of orphan-drug exclusive approval from U.S. Food and Drug Administration (FDA) for Ryoncil ...

2025-05-13 13:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2025-05-13 12:50:39 ET Summary While Mesabi Trust legal expenses should come down and help the bottom line, the royalty report shows that volumes are down in Q1. Moreover, CLF announced a partial idling at Hibbing Taconite amid tougher market conditions, which should affect MSB ro...

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third quarter ended March 31, 2025. “We were very pleased to have ...